Related Experiment Videos
CD44s expression is associated with improved survival in soft tissue sarcoma.
Matthias Peiper1, Takeo Sato, David Zurakowski
1Department of Surgery, Universitätsklinikum Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. matthias.peiper@uni-duesseldorf.de
Anticancer Research
|May 25, 2004
Summary
Standard CD44 (CD44s) expression in soft tissue sarcoma indicates better patient survival and may play a role in tumor progression. This finding could aid in selecting patients for adjuvant therapy.
Area of Science:
- Oncology
- Molecular Pathology
Background:
- CD44 expression is a prognostic factor in various cancers.
- Limited research exists on CD44 expression in soft tissue sarcoma (STS) and its relation to tumor progression.
Purpose of the Study:
- To investigate the clinical significance of standard CD44 (CD44s) expression in adult soft tissue sarcoma (STS).
- To correlate CD44s expression with patient survival and local recurrence rates.
Main Methods:
- Immunohistochemistry was used to evaluate CD44s expression in 62 STS tumor specimens.
- Kaplan-Meier survival analysis and multivariate analysis were employed to assess outcomes.
Main Results:
- 49 out of 62 tumors (79%) were positive for CD44s.
- Patients with CD44s-positive tumors showed significantly better survival (p=0.015).
- CD44s expression, tumor size, and resection quality were independent predictors of survival.
Conclusions:
- CD44s expression is a significant prognostic indicator in soft tissue sarcomas.
- CD44s may have a pathogenetic role in STS progression.
- CD44s expression can help identify STS patients who may benefit from adjuvant treatment.